Clinical Trial Update: SHR0302 Combined With PD-1/PD-L1 Inhibition for Treatment naïve or Acquired Resistant to Immunology NSCLC [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating SHR0302 in combination with PD-1/PD-L1 inhibitors for treatment-naive or immunotherapy-resistant non-small cell lung cancer. The stud…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• PD-1/PD-L1 inhibitor
• SHR0302 (SHR0302)

Snippet

Sponsor: Chunxia Su | Conditions: Non-Small Cell Lung Cancer, JAK Inhibitor | Phase 2 | Status: NOT_YET_RECRUITING